Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester is a complex synthetic organic compound with the molecular formula C23H28N2O5S2. It is classified as a pharmaceutical in the ZINC15 database, suggesting its potential for biological activity and therapeutic applications. The compound incorporates a thiazane ring system, a p-toluenesulfonyl group, and an L-phenylalanine ethyl ester moiety. While specific mechanisms of action and primary indications for this exact compound are not detailed in publicly available information, related thiazine and benzothiazine derivatives are known to exhibit a broad spectrum of pharmacological properties, including anticancer, antimicrobial, anti-inflammatory, and analgesic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester.